BeOne Medicines (NASDAQ:ONC) SVP Chan Henry Lee Sells 10,671 Shares

BeOne Medicines Ltd. – Sponsored ADR (NASDAQ:ONC) SVP Chan Henry Lee sold 10,671 shares of the firm’s stock in a transaction that occurred on Wednesday, October 8th. The shares were sold at an average price of $350.40, for a total value of $3,739,118.40. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Chan Henry Lee also recently made the following trade(s):

• On Wednesday, September 10th, Chan Henry Lee sold 10,006 shares of BeOne Medicines stock. The shares were sold at an average price of $325.53, for a total value of $3,257,253.18.
• On Wednesday, August 13th, Chan Henry Lee sold 11,013 shares of BeOne Medicines stock. The shares were sold at an average price of $300.45, for a total value of $3,308,855.85.
• On Wednesday, July 30th, Chan Henry Lee sold 920 shares of BeOne Medicines stock. The shares were sold at an average price of $304.60, for a total value of $280,232.00.

BeOne Medicines Stock Performance

Shares of ONC opened at $320.10 on Friday. The business’s fifty day simple moving average is $322.42 and its two-hundred day simple moving average is $276.58. The company has a current ratio of 1.95, a quick ratio of 1.72 and a debt-to-equity ratio of 0.04. BeOne Medicines Ltd. – Sponsored ADR has a 12 month low of $170.99 and a 12 month high of $355.30. The company has a market cap of $35.08 billion, a price-to-earnings ratio of -185.03 and a beta of 0.31.

BeOne Medicines (NASDAQ:ONC) last issued its earnings results on Wednesday, August 6th. The company reported $0.84 EPS for the quarter, beating the consensus estimate of $0.48 by $0.36. BeOne Medicines had a negative return on equity of 1.22% and a negative net margin of 3.89%.The business had revenue of $1.32 billion for the quarter, compared to the consensus estimate of $1.24 billion. Research analysts anticipate that BeOne Medicines Ltd. – Sponsored ADR will post -5.82 earnings per share for the current fiscal year.

Hedge Funds Weigh In On BeOne Medicines

A number of institutional investors have recently bought and sold shares of the stock. Primecap Management Co. CA bought a new position in BeOne Medicines in the 2nd quarter worth $1,231,720,000. Temasek Holdings Private Ltd bought a new position in BeOne Medicines in the 2nd quarter worth $244,603,000. Marshall Wace LLP bought a new position in BeOne Medicines in the 2nd quarter worth $113,190,000. Baird Financial Group Inc. bought a new position in BeOne Medicines in the 2nd quarter worth $82,895,000. Finally, Connor Clark & Lunn Investment Management Ltd. bought a new position in BeOne Medicines in the 2nd quarter worth $73,347,000. 48.55% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several analysts have commented on the company. Zacks Research upgraded BeOne Medicines from a “hold” rating to a “strong-buy” rating in a research note on Thursday, September 18th. Weiss Ratings restated a “sell (d-)” rating on shares of BeOne Medicines in a research note on Wednesday. Royal Bank Of Canada raised their price target on BeOne Medicines from $349.00 to $364.00 and gave the stock an “outperform” rating in a research note on Thursday, August 7th. Wall Street Zen upgraded BeOne Medicines from a “buy” rating to a “strong-buy” rating in a research note on Friday, October 3rd. Finally, JPMorgan Chase & Co. raised their price target on BeOne Medicines from $345.00 to $385.00 and gave the stock an “overweight” rating in a research note on Wednesday. One equities research analyst has rated the stock with a Strong Buy rating, eight have issued a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $340.30.

BeOne Medicines Company Profile

BeOne Medicines Ltd. is a global oncology company domiciled in Switzerland that is discovering and developing innovative treatments that are more affordable and accessible to cancer patients worldwide. The firm portfolio spanning hematology and solid tumors, BeOne is expediting development of its diverse pipeline of novel therapeutics through its internal capabilities and collaborations.